Fellowship Faculty

Dr. Jasmine Gujral is an Assistant Professor of Pediatrics in the Division of Pediatric Endocrinology at the Yale School of Medicine and the Yale New Haven Hospital. She received her medical degree at Lokmanya Tilak Municipal Medical College, Mumbai, India and completed her residency in Pediatrics at the Children's Hospital at Saint Peter's University Hospital, New Jersey. She completed her fellowship training at the Icahn School of Medicine at Mount Sinai, New York, where her main research was focused on characterizing growth hormone - immune interactions by means of using multi-omic techniques such as mass spectrometry, proteomics, metabolomics and transcriptomics. Dr. Gujral's research interests include growth disorders, adrenal disorders and disorders of sexual development.

Dr. Boulware has an interest in disorders of growth and development having published several papers looking at the metabolic actions of IGF-1, a hormone critical to childhood growth.  She provides care to children with general disorders of the endocrine system (pituitary, thyroid, adrenal, testes or ovaries).  She is the pediatric endocrinologist in the interdisciplinary Yale Clinic for Children with Differences in Sex Development and she is the Medical Director of the Interdisciplinary Yale Gender Program offering care to gender-expansive youth.

Dr. Braun is a pediatric endocrinologist and clinical researcher. She completed her medical degree and pediatrics training at Mount Sinai, followed by fellowship training in pediatric endocrinology at Massachusetts General Hospital and Harvard Medical School. During her fellowship, she led a clinical trial examining the effects of pitavastatin on insulin sensitivity and liver fat (Braun et al, JCEM, 2018). Prior to arriving at Yale, she was on faculty (Instructor of Pediatrics) at Massachusetts General Hospital and Harvard Medical School, where she treated patients in pediatric endocrinology clinic and performed clinical research in the Metabolism Unit.  Dr. Braun join the Division of Pediatric Endocrinology and Diabetes, where she will participate in the clinical activities, including seeing patients in inpatient units, the diabetes clinic and pediatric endocrine clinic.

I have been involved in Patient-Oriented Research in the field of Childhood Obesity and Type 2 diabetes (T2D) in youth for the past 25 years. Realizing the need to understand the pathophysiology and to find better treatments for  T2D in Obese Youth,  I have been investigating the role of insulin resistance and beta-cell dysfunction at the earliest stage of T2D, namely Impaired Glucose Tolerance (IGT).  My research in pre-diabetes in obese children and adolescents has brought into focus at the national level the magnitude of the obesity problem in children in the US. This research demonstrated a much faster tempo of progression of beta-cell failure in obese adolescents, which helped to stimulate the funding of two NIDDK RCTs in obese youth; The TODAY and RISE studies. In recognition of the importance of this work, in 2008 Dr. Caprio was awarded the prestigious “Distinguished Clinical Scientist Award (DCSA)” from the American Diabetes Association. Her research spans both clinical and basic research in metabolism, genetics, and imaging and is the recipient of the “Distinguished Leader in Insulin Resistance” 2015 Award from the International Committee for Insulin Resistance (ICIR). Over the past decade, our group has assembled two large multiethnic cohorts of children/adolescents cohorts: The Pathogenesis of Youth Onset Diabetes (PYOD) study (NCT01967849), (R01HD040787, R01DK111038), and The Yale Pediatric NAFLD/NASH Cohort  (NCT01966627), which served as the vehicle for a series of studies aimed at investigating the roles of insulin resistance, beta-cell dysfunction and NAFLD in the earliest stage of T2D: Impaired Glucose Tolerance (IGT).

Dr. Carpenter has maintained a career-long involvement in metabolic bone diseases in children. He currently serves as director of the Yale Center for X-linked Hypophosphatemia (XLH) and as the Medical Director of the Yale Center for Clinical Investigation's Hospital Research Unit. His research interests center on the pathophysiology and development of therapy for XLH, the most common inherited form of rickets. He also has a major interest in the metabolism and function of vitamin D, and disorders related to vitamin D in children. He has published over 200 articles, reviews and chapters with a focus of metabolic bone diseases in children, and is currently an Associate Editor of the Journal of Bone and Mineral Research.

Catherine Dinauer, MD is a Pediatric Endocrinologist whose primary focus is care of children with thyroid disorders. She earned her undergraduate degree at Dartmouth College and her medical degree at the University of Vermont College of Medicine. Dr. Dinauer completed Pediatric residency at Walter Reed Army Medical Center in Washington, D.C. and Pediatric Endocrinology fellowship through the National Capitol Area Pediatric Consortium at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland. Following her training, Dr. Dinauer served as an Attending in Pediatric Endocrinology at Walter Reed, worked in research administration as Assistant Chief of the Department of Clinical Investigation, and was an Assistant Professor of Pediatrics at USUHS. Since 2006, her clinical practice has focused on pediatric thyroid disorders, with particular interest in Graves disease, thyroid nodules and pediatric thyroid cancer. She was a member of the American Thyroid Association committee which published guidelines in 2015 on the management of thyroid nodules and thyroid cancer in children and is a member of the committee established in 2020 to revise the guidelines.

Dr. Brian J. Feldman received his combined MD and PhD from Stanford University. He completed a residency in Pediatrics at Children’s Hospital Boston/ Harvard University followed by subspecialty training in Pediatric Endocrinology at the University of California, San Francisco (UCSF). Dr. Feldman then launched his independent research laboratory at Stanford University. He moved to UCSF in 2018 to become the inaugural Walter L. Miller Endowed Chair and Distinguished Professorship in Pediatric Endocrinology. Dr. Feldman has established a widely recognized international reputation for high-impact and cutting-edge research that is particularly relevant for human health. His current work broadly concerns the role of steroid hormones in determining cell fate, initially focusing on glucocorticoid-induced circadian alterations in carbohydrate metabolism, and more recently on the genesis of brown fat. His work has direct bearing on obesity, Type 2 diabetes and the determination of cell fate, and identified novel druggable targets. The impact of these discoveries has been repeatedly recognized with prestigious awards throughout his career. These include being awarded the coveted Clinical Scholars Award from the Pediatric Endocrine Society. He received the celebrated Young Investigator Award from the Society for Pediatric Research. He also received the Early Investigator Award from the Endocrine Society. He was awarded the NIH Director’s New Innovator Award. For his contributions as a physician-scientist, he was elected to membership into The American Association for Clinical Investigation (ASCI). Dr. Feldman is also dedicated to foster the career development of physician-scientists. He continuously volunteers his time to this mission.

Alfonso Galderisi, MD, PhD, is a pediatric endocrinologist who completed his training in Italy at the University of Padova. At the university of Padova he conducted the first trial using continuous glucose monitoring to adjust glucose intakes of very preterm infants, followed by a large Cooperative European Study aimed to identify the effects of early glucose changes on neonatal brain. During his research fellowship at Yale University in 2016 he worked on the role of the incretins as determinants of beta cell function in children with obesity. More recently, by the use of metabolic modelling, his research focused on the physiopathology of insulin sensitivity and secretion in the early stages of T1D. His research areas include the physiology of insulin secretion and sensitivity in children with T1D and T2D and the early neonatal glucose metabolism. His research had been supported by the European Commission (while he was assistant professor of Pediatrics in Italy) and by the Juvenile Diabetes Research Foundation.

Dr. Genel joined the medical school faculty in September 1971 and was Associate Dean, Government and Community Affairs at Yale School of Medicine 1985-2004. Previously he was chief of the section of pediatric endocrinology and program director of the Children's Clinical Research Center. He is the author or co-author of more than 140 original articles and has made numerous presentations at national and international scientific meetings.Dr. Genel has served at the interface between biomedical research, clinical endocrinology and public policy in many capacities. He was a member of the National Children's Study Federal Advisory Committee from 2005-2008, the HHS Secretery's Advisory Committee on Human Research Protections(SACHRP) from 2006-2009 and a charter member of the Institute of Medicine's Clinical Research Roundtable which met from 2000-2004. He is a founder of the Connecticut Stem Cell Coalition and since 2005 has been a member of Connecticut's Stem Cell Research Advisory Committee which oversees distribution of $100 million in state funds to support embryonic stem cell research. Dr. Genel has been a consultant to the International Olympic Committee's Medical Commission on issues relating to gender identity in elite athletic competition.Dr. Genel was elected to the Connecticut Academy of Science and Engineering in 1992, has been a member of its executive council since 2000 and the Academy's president for two years beginning July 2008. For twenty-seven years beginning in 1984 he directed the public affairs activities of three major pediatric academic and research societies: the American Pediatric Society, the Association of American Medical School Department Chairs and the Society for Pediatric Research. Dr. Genel was a member of the AMA Council on Scientific Affairs for seven years, serving as its chair in l999-2000, and of the governing council of the AMA Section on Medical Schools for ten years, serving as the section's chair 2003-2004. A Distinguished Service member of the Association of American Medical Colleges(AAMC), he was chair of the AAMC's Council of Academic Societies in 1990-91. Dr. Genel is the recipient of a number of awards including the Abraham Jacobi Memorial Award from the AMA and the American Academy of Pediatrics(AAP) in 1999, the Distinguished Service Award from the Society for Pediatric Research in 2003, the Joseph W. St. Geme, Jr. Leadership Award from the Federation of Pediatric Organizations in 2004 and the Presidents Award for Distinguished Service from the American Academy of Pediatrics in 2010.

I am the Director and co-founder of the Yale Pediatric Gender Program (YPGP), an interdisciplinary team that provides services for transgender and gender expansive (TGE) youth and families in Connecticut. The team includes professionals in the fields of psychology, endocrinology, psychiatry, gynecology, reproductive medicine, medical ethics and law. Our mission is to provide comprehensive, interdisciplinary, family-centered care for children, adolescents and young adults questioning their assigned gender and/or seeking gender-affirming consultation and care in a compassionate, respectful and supportive environment. This program is regionally well-regarded, serving clients from all 8 counties in the state, as well as 4 states outside of Connecticut. My contribution to the educational mission of Yale’s School of Medicine focuses on teaching trainees in clinical and research training programs about (a) trauma-informed care, (b) psychosexual development, and (c) gender development. Teaching occurs through the delivery of clinical services, mentoring of clinical and research trainees, clinical supervision, and lectures offered in graduate courses and topical seminars coordinated by other faculty members. I have been lucky to mentor and supervise many students in the departments of Psychiatry, the Child Study Center, the School of Public Health and the Divinity School during my tenure at Yale.

1993-1999 Student of Medicine at the Second University of Naples (Napoli – Italy) 1997-1999 Intern, Pediatrics, Department of Pediatrics Second University of Napoli (Napoli, Italy) 2000-2005 Resident, Pediatrics, Department of Pediatrics Second University of Napoli (Napoli, Italy) 2003 Visiting Scientist Human Genomics Lab directed by Dr Claude Bouchard at Pennington Biomedical Research Center (Louisiana State University), Baton Rouge, LA, USA. 2005-2008 PhD student of Pharmacology and Respiratory Pathophysiology, at the Second University of Napoli (Napoli, Italy) 2009-2010 Post doctoral research associate, Department of Pediatrics Yale University (New Haven, CT) 2011-2017 Associate Research Scientist, Department of Pediatrics, Yale University (New Haven, CT) 2017-2020 Assistant Professor, Department of Pediatrics, Yale University (New Haven, CT) 2020- Associate Professor, Department of Pediatrics, Yale University (New Haven, CT)

Jennifer Sherr MD, PhD’s passion for the care of those with type 1 diabetes (T1D) is quite personal, as she was diagnosed in 1987. From the time of her diagnosis, she was determined to become a pediatric endocrinologist. She completed her undergraduate and medical school training through an accelerated Joint BA/MD program at Rutgers University and the University of Medicine and Dentistry of New Jersey- Robert Wood Johnson Medical School. She then completed both her pediatric residency and pediatric endocrinology fellowship at Yale. While she always wanted to care for those with T1D, her eyes were open to the meaningful impact that clinical research has. She thus embarked on further training through the Yale Graduate School of Arts and Sciences Investigative Medicine Program, a PhD program designed to develop the next generation of physician scientists. Dr. Sherr has been devoted to clinical research since 2006. Her thesis examined the mechanisms responsible for the loss of the glucagon response to hypoglycemia and its relationship to residual beta-cell function. She is an expert in the field of diabetes technology and has worked on trials of continuous glucose monitors and automated insulin delivery systems. She has previously worked on projects with the type 1 diabetes exchange (T1DX) and was selected as the first Junior Pediatric Faculty Member to the T1DX Steering Committee, serving in that role from 2016-2017. Working in an NIH-funded consortium, she is co-leading the Yale site to characterize glycemia across pregnancy.  In 2021, she took on the role of lead investigator at Yale for the TrialNet consortium, a group whose purpose is to prevent progression to stage 3 diabetes and preserve residual beta cell function in those who are newly diagnosed with this condition. As a Professor in the department of pediatrics, her goal in both the clinical and research realm is to reduce the burden of living with type 1 diabetes, for both her patients and herself.

Dr. Stephan Siebel is an assistant professor of pediatrics (endocrinology) at Yale School of Medicine. After earning his MD from the Heinrich Heine University, he completed his residency training in general pediatrics, clinical and biochemical genetics before completing a pediatric endocrinology fellowship and his PhD in the Investigative Medicine Program at Yale University. He is the Technical Director of the Chemical Metabolism Core and a research member of the Kibbey Lab. For the core, he is in charge of targeted and untargeted metabolomics, lipidomics and stable isotope based metabolic flux analyses. His research interests focus on the role of central carbon metabolism in the pathogenesis of diabetes mellitus and obesity.

William V. Tamborlane, MD, received his undergraduate BS degree from Georgetown University and was also a graduate of Georgetown University School of Medicine, where he completed his residency in pediatrics before going to Yale as a postdoctoral fellow in pediatric endocrinology. His scientific accomplishments over the past 45 years have established his international reputation as one of the most highly regarded clinical scientists in childhood diabetes and related disorders. He has published more than 1,000 original articles, chapters and reviews in the area of diabetes. Major accomplishments have included pioneering studies in the development of insulin pump therapy, direction of the Yale Center in the NIDDK-sponsored DCCT/EDIC and GRADE studies, and investigations of diabetes-induced defects in counterregulatory hormone responses to hypoglycemia. The prime focus of his work has been in patient-oriented studies in type 1 and type 2 diabetes and related metabolic and endocrine disorders. The hallmark of his research has been to overcome metabolic, physiologic and psychological obstacles to successful management of diabetes. Current research effort is focused on applying recent advances in diabetes technology towards the development of an artificial pancreas for individuals with type 1 diabetes and the study of new treatments of childhood obesity and type 2 diabetes. He is the recipient of many awards and honors and is frequently listed in publications of distinction, including American Men and Women of Science, The Best Doctors in America, America’s Top Doctors and America’s Top Pediatricians. In 2006 and 2011, he was awarded the Mary Tyler Moore and S. Robert Levine Award for Excellence in Clinical Research in Type 1 Diabetes by the Juvenile Diabetes Research Foundation. he has also received  the 2009 Diabetes Technology Society’s Diabetes Technology Leadership Award, the 2010 American Diabetes Association Outstanding Physician Clinician Award, the 2014 National Award for Career Achievement and Contributions to Clinical, the Translational Science by ACRT/SCTS/AFMR, the 2014 Diabetes Prize for Achievement by the International Society for Pediatric and Adolescent and the 2017 American Diabetes Association award for Outstanding Achievement in Clinical Diabetes Research. He has served on the FDA’s Endocrine Advisory Board, on the National Board of Directors of the American Diabetes Association, was the first Steering Committee Chair of the Diabetes Research in Children Network, is the Founder and Chair of the Pediatric Diabetes Consortium and former Vice Chair (for Pediatrics) of the T1D Exchange Clinic Registry. He leads a multidisciplinary team of physicians, diabetes nurse educators, dieticians and social workers that care for more than 1000 children, adolescents and young adults with diabetes. He has also been the mentor of many young physician scientists in their training and career development in clinical research in diabetes.

Michelle Van Name, MD, is an Assistant Professor of Pediatrics in Endocrinology and Diabetes at Yale School of Medicine.  Dr. Van Name obtained her undergraduate degree at Boston College and studied medicine at SUNY Downstate. She then completed her residency training in Pediatrics at Yale as well as additional fellowship in Pediatric Endocrinology, after which she has remained on faculty at Yale. Dr. Van Name was drawn to pediatric medicine because she enjoys teaching children how they can improve their health.Her clinical interest is treating children with type 1 diabetes, type 2 diabetes, and obesity. She leads the adolescent bariatric surgery program for adolescents interested in sleeve gastrectomy for treatment of obesity and its related medical conditions.Dr. Van Name's research focuses on improving diabetes management in populations struggling to meet glycemic targets, including through the use of diabetes technology and other interventions.  Given her interest in both type 1 diabetes and obesity, she is also exploring the intersection of diabetes, obesity, and insulin resistance in adolescents. Further, she is working to determine if medications approved for adults to treat type 2 diabetes are safe and efficacious in children with type 2 diabetes.